Latest Content

Cencora's Ameer Ali explains how the shift to NDC-12 is reshaping supply chain systems and why readiness still varies widely across manufacturers.

HDA's Kala Shankle explains what a national licensure standard could mean for wholesale distributors and 3PLs, and why its success depends on how much state-level variation remains.

Alexis Cogswell of Inizio Medical explains how combining real-world data, AI analysis and HCP context is helping medical affairs teams move from retrospective reporting to actionable, real-time strategy.

Ahead of HDA's 2026 Traceability Seminar, Cencora's Gregg Gorniak explains how AI and RFID are being used to catch DSCSA data gaps before trucks reach the dock.

In this week's Pharma Pulse, new Medicaid pricing deals are rumored, employer GLP-1 pullback, and McKesson's $2.25B oncology buy.

As pharmaceutical companies scale their use of AI across drug safety operations, the Council for International Organizations of Medical Sciences Working Group XIV's now-published guidance sets the bar for what will be required for sustained system validation.

Cardinal Health's Michelle Britt discusses the policy changes needed to secure independent pharmacy's future, from state advocacy wins to giving pharmacists a seat at the table.

TrumpRx has topped 800 drugs since its February launch, but managed care skepticism over real patient savings persists.

Virtual care's pre- and post-visit windows offer pharma marketers a more targeted, attentive audience than physical waiting rooms, new research shows, and most brands aren't capitalizing on it yet.

Health care's real challenge isn't more data, it's activation. Arcadia's Sandy Leonard on turning real-world evidence into point-of-care action.

Cardinal Health's Michelle Britt discusses how independent pharmacies are expanding clinical services and leaning on distributor partnerships to meet evolving patient and community needs.

AMCP's Adam Colborn discusses survey findings on TrumpRx's six-month performance, examining payer skepticism about pricing claims and pharmacy access hurdles for patients.

EVERSANA's Vikram Anand explains how disconnected PV systems and manual safety processes can create commercial delays after FDA approval.